04 June 2009 /Prices and reimbursement
Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation
The Reimbursement Committee's recommendation on the future reimbursement status of laxatives (ATC groups A06 and A02AA04) has been open for consultation until 27 May 2009.
04 June 2009 /Prices and reimbursement
Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation
The Reimbursement Committee's recommendation on the future reimbursement status of antiobesity preparations, excl. diet products (ATC group A08) has been open for consultation until 25 May 2009.
03 June 2009 /Side effects and trials
The European Medicines Agency (EMEA) has raised concern about a possible risk of interaction between medicinal products that contain clopidogrel and proton pump inhibitors (PPI).
14 May 2009 /News - miscellaneous
A number of medicines are available on the market for the treatment of life-threatening obesity. Most of these products are sold on prescription, but just recently a new medicine called Alli® was launched for over-the-counter sale.
13 May 2009 /Side effects and trials
In a new study in rats, scientists from the Italian Instituto di Neuroscienze in Pisa have discovered that Botulinumtoxin A injected into the jaw muscle of rats had found its way to the rats' brains three day after and that it was still present in the rats' brains after six months.
11 May 2009 /Product information
The European Medicines Agency, EMEA, has reassessed the use of Tamiflu® in pregnant women and infants who are ill with influenza A(H1N1).
07 May 2009 /Product information
Stop using Hydroxycut pills, powder and capsules and talk to your doctor about possible side effects or symptoms of liver damage (jaundice, darkening of urine, nausea, vomiting, light-coloured stools, excessive fatigue, stomach or abdominal pain, itching and loss of appetite).
06 May 2009 /Side effects and trials
Voluntary Harmonisation Procedure (VHP) for the assessment of multinational clinical trial applications
The Voluntary Harmonisation Procedure is a procedure which makes it possible to obtain a coordinated assessment of an application for a clinical trial that is to take place in several European countries.
04 May 2009 /Prices and reimbursement
Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
04 May 2009 /News - miscellaneous
The computer security company McAfee has reported floods of spam e-mails that attempt to exploit people who worry about the swine flu.
04 May 2009 /Product information
From today, pharmacies across Denmark will be offering the weight-loss product Alli®. Alli® contains the active ingredient orlistat, which has been authorised in Denmark and other EU countries since 1998 as a prescription-only weight-loss product.
01 May 2009 /Retail and online sale
It is easy to find and buy potency-enhancing pills on the internet. Unfortunately, many of them are not approved by the authorities. This means that they may be detrimental to your health.
30 April 2009 /Prices and reimbursement
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A08 (antiobesity preparations, excl. diet products).
28 April 2009 /Retail and online sale
As early as Saturdag, the first spam e-mails offering Tamiflu® were circulated, only shortly after the first reports on swine influenza in Mexico had reached the media.
16 April 2009 /Side effects and trials
Recently, the Danish Medicines Agency has recorded an increase in the number of reported side effects from Eltroxin. The increase is observed after GlaxoSmithKline (GSK) has changed the excipients contained in Eltroxin.
03 April 2009 /Authorisation and supervision
Until 16 December 2009, the Danish Medicines Agency accepts time slot requests for the first half of 2011 for DCP procedures with Denmark as Reference Member State (RMS)
03 April 2009 /Product information
AstraZeneca has identified a problem with the NES-Spacer®, which is an inhalation device to be used together with asthma medicine. If a patient assembles the NES-Spacer® incorrectly, the patient cannot inhale the medicine, and the simultaneous use of a face mask prevents the patient from breathing.
12 March 2009 /Authorisation and supervision
Project on the monitoring of compliance with the rules by manufacturers of active pharmaceutical ingredients
Since December 2005, active pharmaceutical ingredients (API) used in medicinal products with a marketing authorisation in Denmark have been required to be manufactured under the EU-GMP.
11 March 2009 /Side effects and trials
This is the statement of the Danish Medicines Agency following close scrutiny of all 174 reported adverse reactiong from the new HPV vaccine against cervical cancer - Gardasil®.
25 February 2009 /Side effects and trials
The benefits of the medicine exceed the risks when children and young people with activity and attention problems - ADHD (attention deficit hyperactivity disorder) - are given medicine containing the substance methylphenidate.